Dose Level 1
Sponsors
Baylor College of Medicine, Pfizer, Brown University, Jichi Medical University, Woodmont Pharmaceuticals, Inc.
Conditions
Allergic ConjunctivitisAllergic RhinitisHPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical StageHigh Grade Serous Ovarian CancerLeukemiaLeukemia, B-Cell, ChronicMetastatic Pancreatic CancerOropharynx Cancer
Phase 1
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
CompletedNCT00058799
Start: 1999-06-30End: 2010-06-30Updated: 2020-01-21
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
CompletedNCT00078520
Start: 2003-01-31End: 2010-03-31Updated: 2020-01-21
Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis
CompletedNCT00838565
Start: 2009-05-20End: 2012-02-02Updated: 2018-11-02
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
CompletedNCT01744353
Start: 2012-11-30End: 2015-08-31Updated: 2020-02-17
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
NCT02134262
Start: 2014-05-31End: 2017-03-31Target: 18Updated: 2014-11-06
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
TerminatedNCT03038971
Start: 2017-03-30End: 2017-04-29Updated: 2018-02-26
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
RecruitingNCT06976892
Start: 2025-08-31End: 2029-12-31Target: 33Updated: 2025-08-13